Agents make "preferred list" in metastatic melanoma.
The 2014 version of the NCCN Guidelines for Melanoma lists 6 preferred regimens, most with a category 1 recommendation, and 8 "other active regimens." Effective new agents include ipilimumab, a monoclonal anti-CTLA4 antibody, and agents targeted against mutated BRAF and MEK. Researchers are now focused on the optimal way to combine or sequence these agents, while exploring other new classes.
Presented by John A. Thompson, MD, Co-Director, Melanoma Clinic, Seattle Cancer Care Alliance, Seattle, Washington.
John A
JA
Thompson
D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D058990:Molecular Targeted Therapy; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*